ArticleThe journal of allergy and clinical immunology. Global2026
Characteristics associated with rapid chronic rhinosinusitis with nasal polyp recurrence following endoscopic sinus surgery in NSAID-exacerbated respiratory disease.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD) or aspirin-exacerbated respiratory disease are prone to rapid recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP) after endoscopic sinus surgery (ESS), often resulting in persistent symptoms and reduced quality of life. Objective: We sought to determine patient-reported timing and associated symptoms of CRSwNP recurrence after ESS, as well as to assess whether current disease burden differs by prior recurrence timing. Methods: We analyzed data from 325 participants in our NSAID-ERD registry who reported a history of prior ESS. At registry enrollment, patients were asked to recall the time to recurrence of CRSwNP following their most recent ESS (≥2 years before enrollment). At enrollment, participants also completed the 22-Item Sino-Nasal Outcome Test (SNOT-22) and Asthma Control Test (ACT) questionnaires, reflecting current sinonasal and asthma disease burden. In a separate follow-up survey, a larger cohort of participants were asked to report the symptoms that they experienced with CRSwNP recurrence. Results: The median patient-reported time to post-ESS CRSwNP recurrence was 6 months, with 51.1% reporting recurrence in 6 months or less, 18.2% reporting recurrence in 6 to 12 months, 15.4% reporting recurrence in 12 to 24 months, and 15.4% reporting no recurrence at 24 months. The most common symptoms reported with CRSwNP recurrence were nasal congestion (91.3%) and hyposmia/anosmia (86.6%). At registry enrollment, those with fast recurrence (≤6 months) had higher total SNOT-22 scores (52.4 ± 23.6 vs 39.7 ± 20.3 [ Conclusions: Post-ESS CRSwNP recurrence in patients with NSAID-ERD was most often signaled by worsening nasal congestion and loss of smell. Patients with fast CRSwNP recurrence later exhibited greater overall respiratory disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.